Wearable light blood sugar reducing device, system and eyeshade

Abstract

The invention relates to the technical field of phototherapy, in particular to a wearable light blood sugar reducing device and system and an eyeshade. The wearable light hypoglycemic device comprises a wearing unit for a user to wear; the lighting unit is used for projecting red light to human eyes; the driving unit is used for supplying power to the lighting unit; and the control unit is used for adjusting the light-emitting mode of the lighting unit according to a preset regulation and control scheme. According to the preset regulation and control scheme, multiple times of illumination are carried out within preset time, and the interval between every two adjacent times of illumination is preset duration. Red light waves of a specific wave band can be emitted to human eyes according to a preset regulation and control scheme, photosensitive retinal ganglion cells (ipRGCs) can be directly activated, signals are transmitted from optic nerves to series nerve nuclei of hypothalamus and medulla oblongata, finally, the signals act on peripheral brown adipose tissue BAT through sympathetic nerves, the metabolic capacity of blood sugar is affected, and the blood sugar metabolism is improved. And when the embodiment is used for reducing blood sugar, the user only needs to wear the equipment, so that the method is easy to implement.

Description

Technical Field

[0001] The present invention relates to the technical field of phototherapy, and in particular to a wearable photo-induced blood sugar lowering device, system and eye mask. Background Art

[0002] Hyperglycemia, also known as hyperglycemia in medicine, refers to the concentration of glucose in the blood exceeding the normal value. If this condition persists for a long time, it may cause damage to multiple important organs of the body, including but not limited to the cardiovascular system, nervous system, kidneys and eyes, thereby increasing the incidence of related diseases.

[0003] Currently, there are two main ways to manage blood sugar levels: one is non-drug methods, such as controlling weight by adjusting eating habits and increasing physical activity; the other is drug treatment, including taking oral hypoglycemic drugs or insulin injections to help regulate blood sugar. These two methods can be used alone or in combination to achieve the best blood sugar control effect.

[0004] However, managing blood sugar with non-drug methods such as diet control and exercise weight loss may be challenging for many people. On the one hand, following a strict diet plan or maintaining a regular exercise habit requires strong self-discipline; on the other hand, even if rapid weight loss is achieved in a short period of time, weight rebound is likely to occur if a healthy lifestyle is not maintained. In addition, although the use of drug treatments to control blood sugar is effective, it may also be accompanied by certain side effects or restrictions on use. Different types of hypoglycemic drugs have different potential adverse reactions, the most common of which include gastrointestinal discomfort, diarrhea, nausea and other symptoms. When choosing an appropriate drug treatment plan, the doctor will comprehensively consider the patient's specific situation to ensure the safety and effectiveness of the treatment; in other words, some patients may not be able to control their blood sugar through drug treatments due to their physical condition.

[0005] In view of the adverse reactions that may be caused by drug treatment to control blood sugar, and the fact that non-drug measures such as diet control and exercise weight loss require patients to have a high degree of self-discipline, it is particularly necessary to develop a convenient and easy-to-use glucose control device. Such a device can not only help patients manage blood sugar levels more effectively, but also reduce the challenges they face during treatment and improve their quality of life. Summary of the invention

[0006] The purpose of the present invention is to overcome the existing non-drug blood sugar control measures such as diet control and exercise weight loss, which are often difficult to implement and difficult to implement for a long time; although drug blood sugar control is an effective means, its possible side effects or existing drug contraindications cannot be ignored, and provide a wearable light blood sugar lowering device, system and eye mask.

[0007] In the first aspect, the present invention provides a wearable light-induced blood sugar lowering device, comprising: a wearable unit for being worn by a user; a lighting unit for projecting red light to the human eye; a driving unit for supplying power to the lighting unit; and a control unit for adjusting the power supply parameters of the driving unit according to a preset control scheme, thereby adjusting the light-emitting mode of the lighting unit. The power supply parameters at least include the duration of the current output. The preset control scheme is to perform several illuminations within a preset time, and the interval between two adjacent illuminations is a preset duration.

[0008] According to a preferred embodiment, the preset control scheme is to perform lighting 2-12 times within a preset time, and the interval between two adjacent lightings is 10-30 minutes.

[0009] According to a preferred embodiment, the preset control scheme is to perform four illuminations. The first illumination lasts for a duration of T1. The second illumination lasts for a duration of T3, and the first illumination and the second illumination are separated by a duration of T2. The third illumination lasts for a duration of T5, and the second illumination and the third illumination are separated by a duration of T4. The fourth illumination lasts for a duration of T7, and the third illumination and the fourth illumination are separated by a duration of T6.

[0010] According to a preferred embodiment, the red light emitted by the lighting unit is a single-wavelength light, and the wavelength is at least one of 620nm to 710nm.

[0011] According to a preferred embodiment, the red light illuminance projected by the lighting unit to human eyes is less than a first preset illuminance, wherein the first preset illuminance has a value range of 300-600 lx.

[0012] According to a preferred embodiment, the red light emitted by the lighting unit is a broad-spectrum light, and the spectrum range is between 600nm and 710nm.

[0013] According to a preferred embodiment, the illumination of red light projected by the lighting unit to human eye visual perception is greater than 600 lx.

[0014] According to a preferred embodiment, the red light radiation intensity projected by the lighting unit to human eye visual perception is less than 700 mW.

[0015] The present invention also provides a light hypoglycemic eye mask, comprising: a wearing unit, including a cover and a strap; the cover can be worn to the user's eyes through the strap; the lighting unit is arranged on the cover, for projecting red light to the human eye; a driving unit, for supplying power to the lighting unit; a control unit, for adjusting the power supply parameters of the driving unit according to a preset control scheme, thereby adjusting the light-emitting mode of the lighting unit. Wherein, the power supply parameters at least include the duration of the current output; the preset control scheme is to perform a number of illuminations within a preset time, and the interval between two adjacent illuminations is a preset time.

[0016] The present invention also provides a wearable photoblood sugar lowering system, comprising: a photoblood sugar lowering device and a blood sugar detection device. The photoblood sugar lowering device at least comprises: a wearable unit for being worn by a user; a lighting unit for projecting red light to the human eye; a driving unit for supplying power to the lighting unit; and a control unit for adjusting the power supply parameters of the driving unit according to a preset control scheme, thereby adjusting the light emission mode of the lighting unit. The power supply parameters at least include the duration of the current output; the preset control scheme is to perform several illuminations within a preset time, and the interval between two adjacent illuminations is a preset time. The blood sugar detection device is used to detect the blood sugar concentration of the user, and then adjust the preset control scheme.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The present invention provides a wearable light-induced blood sugar lowering device, system and eye mask. When using the present invention, the user can place the lighting unit in front of the eyes through the wearable unit, so that the lighting unit can emit red light to the human eye according to a preset control scheme, so that red light waves in a specific band enter from the visual window, which can directly activate photosensitive retinal ganglion cells ipRGCs (special photoreceptor cells) and transmit signals through the optic nerve to a series of nerve nuclei in the hypothalamus and medulla oblongata, and finally act on the peripheral brown adipose tissue BAT through the sympathetic nerves, which can affect the metabolic capacity of blood sugar, thereby achieving a blood sugar control effect. When using the present invention to lower blood sugar, the user only needs to wear the device, which is easy to implement. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 A schematic diagram of the structure of a wearable light-induced blood sugar lowering device provided by the present invention;

[0020] Figure 2 A schematic diagram of the light-lowering blood sugar eye mask provided by the present invention;

[0021] Figure 3 A schematic diagram of a wearable optical blood sugar lowering system provided by the present invention;

[0022] Figure 4This is a graph showing the 24-hour blood sugar level changes of a test subject who has been suffering from diabetes for three years while taking hypoglycemic drugs;

[0023] Figure 5 A curve chart showing changes in blood sugar levels over 24 hours when the test subject takes hypoglycemic drugs and uses the optical hypoglycemic system provided by the present invention;

[0024] Figure 6 The figure shows the change of blood sugar level of the test subject in 24 hours when the test subject did not take hypoglycemic drugs but used the light hypoglycemic system provided by the present invention.

[0025] Markings in the figure:

[0026] Wearing unit-100, cover-140, strap-150, lighting unit-200, driving unit-300, control unit-400. DETAILED DESCRIPTION

[0027] The present invention is further described in detail below in conjunction with test examples and specific implementation methods. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following embodiments, and all technologies realized based on the content of the present invention belong to the scope of the present invention.

[0028] Unless otherwise specified, in the description of the specific embodiments of the present invention, the terms indicating the orientation or position relationship such as "up", "down", "left", "right", "center", "inside", "outside", etc. are all expressions based on the orientation or position relationship shown in the drawings, or the orientation or position relationship when the invented product / equipment / device is usually used. These terms of orientation or position relationship are only for the convenience of describing the scheme of the present invention or simplifying the description in the specific embodiments, so as to facilitate the technicians to quickly understand the scheme, rather than indicating or implying that a specific device / component / element must have a specific orientation, or be constructed and operated in a specific position relationship, and therefore cannot be understood as a limitation on the present invention.

[0029] In addition, if the terms "horizontal", "vertical", "overhanging", "parallel" and the like appear, it does not mean that the corresponding devices / components / elements are required to be absolutely horizontal or vertical or overhanging or parallel, but may be slightly tilted or have deviations. For example, "horizontal" only means that its direction is more horizontal than "vertical", and does not mean that the structure must be completely horizontal, but may be slightly tilted. Alternatively, it can be simplified to mean that the corresponding devices / components / elements are set in directions such as "horizontal", "vertical", "overhanging", "parallel", etc., and can have an error / deviation of ±10% relative to the corresponding direction setting, more preferably an error / deviation within ±8%, more preferably an error / deviation within ±6%, more preferably an error / deviation within ±5%, and more preferably an error / deviation within ±4%. As long as the corresponding device / component / element is within the error / deviation range, it can still achieve its role in the scheme of the present invention.

[0030] In addition, the expressions “first”, “second”, “third”, etc. that appear in the terms are merely descriptions used to distinguish the same or similar components and should not be understood as emphasizing or implying the relative importance of specific components.

[0031] In addition, in the description of the embodiments of the present invention, "several", "plurality" and "a number" represent at least 2. It can be any number such as 2, 3, 4, 5, 6, 7, 8, 9, and even more than 9.

[0032] In addition, in the description of the technical solution of the present invention, unless otherwise clearly specified / defined / restricted, the terms "set", "install", "connect", "connected", "provided with", "laid", and "arranged" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection, and can be welding, riveting, bolting, threading, and other commonly used connection means in the field. This connection can be a mechanical connection, an electrical connection, or a communication connection; it can be a direct connection, or an indirect connection through an intermediate medium, and it can be the internal connection of two elements.

[0033] Example 1

[0034] This embodiment provides a wearable light-induced blood sugar lowering device. Figure 1Preferably, the wearable photohypoglycemic device provided in this embodiment includes: a wearable unit 100, a lighting unit 200, a driving unit 300 and a control unit 400. The wearable unit 100 is used to be worn by the user; the lighting unit 200 is used to project red light to the human eye; the driving unit 300 is used to supply power to the lighting unit 200; the control unit 400 is used to adjust the power supply parameters of the driving unit 300 according to a preset control scheme, thereby adjusting the light-emitting mode of the lighting unit 200. Preferably, the power supply parameters include at least the duration of the current output. The preset control scheme is to perform several illuminations within a preset time, and the interval between two adjacent illuminations is a preset duration.

[0035] This embodiment provides a wearable light-induced blood sugar lowering device. When using the wearable light-induced blood sugar lowering device, the user can place the lighting unit 200 in front of the eyes through the wearable unit 100, so that the lighting unit 200 can emit red light to the human eye according to a preset control scheme. This embodiment emits red light to the human eye, so that red light waves of a specific band enter from the visual window, which can directly activate photosensitive retinal ganglion cells ipRGCs (special photoreceptor cells), transmit signals through the optic nerve to a series of nerve nuclei in the hypothalamus and medulla oblongata, and finally act on the peripheral brown adipose tissue BAT through the sympathetic nerves, which can affect the metabolic capacity of blood sugar, thereby achieving a blood sugar control effect, and when using this embodiment to reduce blood sugar, the user only needs to wear the device, which is easy to implement.

[0036] Example 2

[0037] This embodiment is a further improvement of the embodiment 1, and the repeated contents are not repeated. In this embodiment, the preset control scheme is to perform 2-12 illuminations within a preset time, and the interval between two adjacent illuminations is 10-30 minutes.

[0038] Preferably, the preset control scheme is to perform four illuminations. The first illumination lasts for a duration of T1. The second illumination lasts for a duration of T3, and the first illumination and the second illumination are separated by a duration of T2. The third illumination lasts for a duration of T5, and the second illumination and the third illumination are separated by a duration of T4. The fourth illumination lasts for a duration of T7, and the third illumination and the fourth illumination are separated by a duration of T6.

[0039] Preferably, the red light emitted by the lighting unit 200 is a single-wavelength light, and the wavelength is at least one of 620nm to 710nm.

[0040] Preferably, the lighting unit 200 may be equipped with a plurality of red light LEDs for emitting red light. The red light LEDs may be red light LEDs with a light emission wavelength of one or several wavelengths in the wavelength band of 620nm to 710nm.

[0041] Preferably, the red light illuminance projected by the lighting unit 200 to the human eye is less than a first preset illuminance, wherein the first preset illuminance has a value range of 300-600 lx.

[0042] Preferably, the red light emitted by the lighting unit 200 is a broad-spectrum light, and the spectrum range is between 600nm and 710nm.

[0043] Preferably, the luminous spectrum range of the lighting unit 200 can be a certain band in the 600-710nm band. Preferably, the lighting unit 200 can use red light LEDs of the same luminous band, so that the wearable visual perception optimization device emits red light of the same band. Preferably, the lighting unit 200 can also use red light LEDs of different luminous bands, so that the wearable visual perception optimization device emits red light of multiple bands.

[0044] Preferably, the red light illuminance projected by the lighting unit 200 to the human eye visual perception is greater than 600 lx.

[0045] Preferably, the red light radiation intensity projected by the lighting unit 200 to the human eye visual perception is less than 700 mW.

[0046] Example 3

[0047] This embodiment provides a light-induced blood sugar lowering eye mask, and this embodiment is a preferred specific implementation of the light-induced blood sugar lowering device involved in Embodiment 1 and Embodiment 2, and the repeated contents will not be repeated.

[0048] The light hypoglycemic eye mask provided in this embodiment includes: a wearing unit 100, a lighting unit 200, a driving unit 300 and a control unit 400. Figure 2 , the wearable unit 100 includes a cover 140 and a strap 150. The cover 140 can be worn to the user's eyes through the strap 150. The lighting unit 200 is arranged on the cover 140, and is used to project red light to the human eye. The driving unit 300 is used to supply power to the lighting unit 200. The control unit 400 is used to adjust the power supply parameters of the driving unit 300 according to a preset control scheme, and then adjust the light-emitting mode of the lighting unit 200. Preferably, the power supply parameters include at least the duration of the current output. The preset control scheme is to perform several lightings within a preset time, and the interval between two adjacent lightings is a preset time.

[0049] Example 4

[0050] This embodiment provides a wearable photoblood sugar lowering system, including: a photoblood sugar lowering device and a blood sugar detection device. The photoblood sugar lowering device involved in this embodiment can be the photoblood sugar lowering device involved in embodiment 1 and embodiment 2, and specifically can be the photoblood sugar lowering eye mask provided in embodiment 3.

[0051] See also Figure 3 , the light hypoglycemic device may include: a wearable unit 100 for being worn by a user; an illumination unit 200 for projecting red light to the human eye; a driving unit 300 for supplying power to the illumination unit 200; and a control unit 400 for adjusting the power supply parameters of the driving unit 300 according to a preset control scheme, thereby adjusting the light-emitting mode of the illumination unit 200. The power supply parameters at least include the duration of the current output; the preset control scheme is to perform several illuminations within a preset time, and the interval between two adjacent illuminations is a preset time. The blood sugar detection device is used to detect the blood sugar level of the user, and then adjust the preset control scheme.

[0052] Preferably, after the blood sugar detection device detects the blood sugar level of the user, the user can manually select a preset control scheme according to the blood sugar level.

[0053] Preferably, the preset control scheme may also be adjusted automatically by the control unit 400 according to the communication with the blood glucose detection device.

[0054] Preferably, this embodiment is provided with at least two preset control schemes. When the blood sugar detection device detects that the blood sugar level of the user is higher than 13, the first preset control scheme is adopted; when the blood sugar detection device detects that the blood sugar level of the user is not higher than 13, the second preset control scheme is adopted.

[0055] Preferably, the blood sugar level detected by the blood sugar detection device is the blood sugar level of the user after the meal, and preferably the blood sugar level detected 10 minutes after the meal.

[0056] Preferably, the wearable light-lowering blood sugar system provided in this embodiment can be used after the user has a meal, specifically, it can be used starting 10 minutes after the meal.

[0057] When using the wearable light-lowering blood sugar system provided in this embodiment, the lighting unit 200 can perform 2-12 illuminations within a preset time, preferably 3-6 illuminations; and the interval between two adjacent illuminations is 10-30 minutes, preferably 15-20 minutes.

[0058] When the lighting unit 200 is lighting, the magnitude of the output current of the driving unit 300 depends on the red light radiation intensity projected by the lighting unit 200 to the visual perception of the human eye and the red light illuminance projected by the lighting unit 200 to the visual perception of the human eye.

[0059] The red light radiation intensity projected by the lighting unit 200 to the human eye visual perception is less than 700 mW.

[0060] The lighting unit 200 is configured with a plurality of light emission modes according to the light emission wavelength and the red light illumination required to be projected to the human eye's visual perception. Preferably, the lighting unit 200 is provided with four light emission modes.

[0061] The first light emission mode: the red light emitted by the lighting unit 200 is a single-wavelength light, and when the wavelength is at least one of 620nm to 710nm, the illuminance of the red light projected by the lighting unit 200 to the human eye's visual perception ranges from 300 to 600lx.

[0062] The second light emission mode: the red light emitted by the lighting unit 200 is a broad-spectrum light, and the spectral range is between 600nm and 710nm. The illuminance of the red light projected by the lighting unit 200 to the human eye is in the range of 600 to 1000lx.

[0063] The third light emission mode: the red light emitted by the lighting unit 200 is a broad-spectrum light, and the spectral range is between 600nm and 710nm. The illuminance of the red light projected by the lighting unit 200 to the human eye is in the range of 1000 to 2000lx.

[0064] The fourth light emission mode: the red light emitted by the lighting unit 200 is a broad-spectrum light, and the spectral range is between 600nm and 710nm. The illuminance of the red light projected by the lighting unit 200 to the visual perception of the human eye is greater than 2000lx.

[0065] Preferably, in each light emission mode, when the blood sugar detection device detects that the user's blood sugar value is higher than 13, the first preset control scheme is adopted; when the blood sugar detection device detects that the user's blood sugar value is not higher than 13, the second preset control scheme is adopted.

[0066] Preferably, in this embodiment, the values ​​of T1 to T7 are set to obtain a preset control scheme in each light emission mode.

[0067] Preferably, in the first light emission mode, when the blood sugar detection device detects that the blood sugar level of the user is higher than 13, the first preset control scheme is: the first illumination lasts for 1-40 seconds. The second illumination lasts for 2-40 seconds, and there is a 20-minute interval between the first illumination and the second illumination. The third illumination lasts for 2-40 seconds, and there is a 20-minute interval between the second illumination and the third illumination. The fourth illumination lasts for 1-40 seconds, and there is a 20-minute interval between the third illumination and the fourth illumination.

[0068] Preferably, in the first light emission mode, when the blood sugar detection device detects that the blood sugar value of the user is not higher than 13, the first preset control scheme is: the first illumination lasts for 1-20 seconds. The second illumination lasts for 2-20 seconds, and there is a 20-minute interval between the first illumination and the second illumination. The third illumination lasts for 2-20 seconds, and there is a 20-minute interval between the second illumination and the third illumination. The fourth illumination lasts for 1-20 seconds, and there is a 20-minute interval between the third illumination and the fourth illumination.

[0069] Preferably, in the second light emitting mode, when the blood sugar detection device detects that the blood sugar level of the user is higher than 13, the first preset control scheme is: the first illumination lasts for 2-40 seconds. The second illumination lasts for 2-270 seconds, and there is a 20-minute interval between the first illumination and the second illumination. The third illumination lasts for 2-270 seconds, and there is a 20-minute interval between the second illumination and the third illumination. The fourth illumination lasts for 2-40 seconds, and there is a 20-minute interval between the third illumination and the fourth illumination.

[0070] Preferably, in the second light emitting mode, when the blood sugar detection device detects that the blood sugar value of the user is not higher than 13, the first preset control scheme is: the first illumination lasts for 2-60 seconds. The second illumination lasts for 2-300 seconds, and there is a 20-minute interval between the first illumination and the second illumination. The third illumination lasts for 2-300 seconds, and there is a 20-minute interval between the second illumination and the third illumination. The fourth illumination lasts for 2-60 seconds, and there is a 20-minute interval between the third illumination and the fourth illumination.

[0071] Preferably, in the third light emitting mode, when the blood sugar detection device detects that the blood sugar level of the user is higher than 13, the first preset control scheme is: the first illumination lasts for 2-20 seconds. The second illumination lasts for 2-40 seconds, and there is a 20-minute interval between the first illumination and the second illumination. The third illumination lasts for 2-40 seconds, and there is a 20-minute interval between the second illumination and the third illumination. The fourth illumination lasts for 2-20 seconds, and there is a 20-minute interval between the third illumination and the fourth illumination.

[0072] Preferably, in the third light emitting mode, when the blood sugar detection device detects that the blood sugar value of the user is not higher than 13, the first preset control scheme is: the first illumination lasts for 2-40 seconds. The second illumination lasts for 2-60 seconds, and there is a 20-minute interval between the first illumination and the second illumination. The third illumination lasts for 2-60 seconds, and there is a 20-minute interval between the second illumination and the third illumination. The fourth illumination lasts for 2-40 seconds, and there is a 20-minute interval between the third illumination and the fourth illumination.

[0073] Preferably, in the fourth light emission mode, when the blood sugar detection device detects that the blood sugar level of the user is higher than 13, the first preset control scheme is: the first illumination lasts for 2-10 seconds. The second illumination lasts for 2-20 seconds, and there is a 20-minute interval between the first illumination and the second illumination. The third illumination lasts for 2-20 seconds, and there is a 20-minute interval between the second illumination and the third illumination. The fourth illumination lasts for 2-10 seconds, and there is a 20-minute interval between the third illumination and the fourth illumination.

[0074] Preferably, in the fourth light emission mode, when the blood sugar detection device detects that the blood sugar value of the user is not higher than 13, the first preset control scheme is: the first illumination lasts for 2-20 seconds. The second illumination lasts for 2-30 seconds, and there is a 20-minute interval between the first illumination and the second illumination. The third illumination lasts for 2-30 seconds, and there is a 20-minute interval between the second illumination and the third illumination. The fourth illumination lasts for 2-20 seconds, and there is a 20-minute interval between the third illumination and the fourth illumination.

[0075] Preferably, the wearable light-induced blood sugar lowering system provided in this embodiment can also be worn by the user for 30-60 minutes after a meal, with continuous light exposure during the wearing process.

[0076] like Figure 4 The figure shows the 24-hour changes in blood sugar levels of a subject who has suffered from diabetes for three years while taking hypoglycemic drugs.

[0077] like Figure 5 The figure shows the 24-hour changes in blood sugar levels of the test subjects while taking hypoglycemic drugs and using a light hypoglycemic system.

[0078] like Figure 6 The figure shows the 24-hour blood sugar level changes of the test subjects when they were not taking hypoglycemic drugs and using the light blood sugar lowering system.

[0079] Figure 4 , Figure 5 , Figure 6 The blood glucose value in the blood is obtained by a blood glucose detection device. Preferably, the blood glucose detection device can be a "Yuyue" dynamic blood glucose monitor.

[0080] according to Figure 4 , Figure 5 and Figure 6 It can be seen that the wearable optical blood sugar lowering system provided in this embodiment can effectively lower blood sugar, especially for the control of postprandial blood sugar, the reduction is more obvious.

[0081] Preferably, the wearable light hypoglycemic system provided in this embodiment can promote the secretion of melatonin while achieving sugar control. Since the lighting unit 200 emits red light, after the red light is irradiated to the retina, the light-sensitive melanopsin possessed by some ganglion cells allows the ganglion cells to transmit light information to the supraoptic nucleus, thereby promoting the production of melatonin.

[0082] Preferably, using the wearable light-lowering blood sugar system provided in this embodiment after a meal can promote the secretion of melatonin while achieving blood sugar control, thereby promoting sleep.

[0083] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A wearable light-induced blood sugar lowering device, characterized in that: include: A wearable unit (100), configured to be worn by a user; An illumination unit (200) for projecting red light toward human eyes; A driving unit (300) configured to supply power to the lighting unit (200); A control unit (400) for adjusting the power supply parameters of the driving unit (300) according to a preset control scheme, thereby adjusting the light emission of the lighting unit (200); Wherein, the power supply parameters at least include the duration of current output; The preset control scheme is to perform lighting several times within a preset time, and the interval between two adjacent lightings is a preset time length.

2. A wearable light-induced blood sugar lowering device according to claim 1, characterized in that: The preset control scheme is to perform lighting 2-12 times within a preset time, and the interval between two adjacent lightings is 10-30 minutes.

3. A wearable light-induced blood sugar lowering device according to claim 2, characterized in that: The preset control scheme is to perform four lighting operations, wherein: The first lighting lasts for T1 duration; The second illumination lasts for T3 duration, and there is a T2 duration between the first illumination and the second illumination; The third lighting lasts for T5 duration, and there is a T4 duration between the second and third lighting; The fourth illumination lasts for a duration of T7, and there is a time interval of T6 between the third illumination and the fourth illumination.

4. A wearable light-induced blood sugar lowering device according to claim 1, characterized in that: The red light emitted by the lighting unit (200) is a single-wavelength light, and the wavelength is at least one of 620nm to 710nm.

5. A wearable light-induced blood sugar lowering device according to claim 4, characterized in that: The illuminance of the red light projected by the lighting unit (200) to human eye visual perception is less than a first preset illuminance; The first preset illumination has a value range of 300-600 lx.

6. A wearable light-induced blood sugar lowering device according to claim 1, characterized in that: The red light emitted by the lighting unit (200) is a broad-spectrum light, and the spectrum range is between 600nm and 710nm.

7. A wearable light-induced blood sugar lowering device according to claim 6, characterized in that: The illumination of red light projected by the lighting unit (200) to human eye visual perception is greater than 600 lx.

8. A wearable light-induced blood sugar lowering device according to claim 1, characterized in that: The red light radiation intensity projected by the lighting unit (200) to human eye visual perception is less than 700 mW.

9. A light hypoglycemic eye mask, characterized in that: include: A wearable unit (100) comprises a cover (140) and a strap (150); the cover (140) can be worn around the eyes of a user via the strap (150); The lighting unit (200) is arranged on the housing (140) and is used to project red light toward human eyes; A driving unit (300) configured to supply power to the lighting unit (200); A control unit (400) for adjusting the power supply parameters of the driving unit (300) according to a preset control scheme, thereby adjusting the light emission of the lighting unit (200); Wherein, the power supply parameters at least include the duration of current output; The preset control scheme is to perform lighting several times within a preset time, and the interval between two adjacent lightings is a preset time length.

10. A wearable light-induced blood sugar lowering system, characterized in that: include: Photohypoglycemic devices and blood sugar testing devices; The light hypoglycemic device at least comprises: A wearable unit (100), configured to be worn by a user; An illumination unit (200) for projecting red light toward human eyes; A driving unit (300) configured to supply power to the lighting unit (200); A control unit (400) for adjusting the power supply parameters of the driving unit (300) according to a preset control scheme, thereby adjusting the light emission of the lighting unit (200); The power supply parameters at least include the duration of the current output; the preset control scheme is to perform lighting several times within a preset time, and the interval between two adjacent lightings is a preset time; The blood sugar detection device is used to detect the blood sugar concentration of the user and then adjust the preset control scheme.

Images